FOR PATIENTS WITH TYPE 2 DIABETES
SIGNIFICANT * HbA1c REDUCTION
– WEIGHT LOSS † 1 – 4 at 102 weeks compared with placebo, in patients taking metformin IR † † Dapagliflozin is not indicated for weight loss. Secondary Endpoint. 1 – 4
– SYSTOLIC BLOOD PRESSURE REDUCTION ‡# 5, 6 on top of background antihypertensive therapy § at 12 weeks compared to placebo 5, 6
XIGDUO XR CONVENIENCE OF ONCE DAILY DOSING 2
FORXIGA
®
( dapagliflozin)
AND XIGDUO
®
XR
( dapagliflozin / metformin HCl extended-release) tablets
FOR PATIENTS WITH TYPE 2 DIABETES
DAPAGLIFLOZIN OFFERS:
SIGNIFICANT * HbA1c REDUCTION
sustained out to 102 weeks when added to metformin IR, compared to placebo plus metformin IR 1 – 4 * Statistically significant; p < 0.0001
Additional benefits:
– WEIGHT LOSS † 1 – 4 at 102 weeks compared with placebo, in patients taking metformin IR † † Dapagliflozin is not indicated for weight loss. Secondary Endpoint. 1 – 4
– SYSTOLIC BLOOD PRESSURE REDUCTION ‡# 5, 6 on top of background antihypertensive therapy § at 12 weeks compared to placebo 5, 6
‡ Dapagliflozin is not indicated for blood pressure reduction. Co-primary endpoint with change in HbA1c. 5, 6 # No significant difference in DBP between groups. 5, 6
§ ARB / ACEi with or without additional antihypertensive agent.
XIGDUO XR CONVENIENCE OF ONCE DAILY DOSING 2
XIGDUO ® XR( dapagliflozin / metformin XR) is bioequivalent to co-administration of approved doses of individual components. 2 Comparable glycaemic control has been shown between metformin immediate( IR) and extended-release( XR) formulations. 7
( dapagliflozin)( dapagliflozin / metformin HCl extended-release) tablets
BEFORE PRESCRIBING PLEASE REVIEW PBS AND PRODUCT INFORMATION AVAILABLE IN THE PRIMARY ADVERTISEMENT IN THIS PUBLICATION OR ON REQUEST FROM ASTRAZENECA.
References: 1. FORXIGA ® Approved Product Information. 2. XIGDUO ® XR Approved Product Information. 3. Bailey CJ et al. Lancet 2010; 375:2223 – 2233. 4. Bailey CJ et al. BMC Medicine 2013; 11; 43:1 – 10. 5. Weber MA et al. Lancet Diab Endocrinol 2016; 4:211 – 220. 6. Weber MA et al. Blood Pressure 2015; 25:93 – 103. 7. Fujioka K et al. Clinical Therapeutics 2003; 25( 2): 515 – 529. DBP = diastolic blood pressure; HbA 1c = haemoglobin A1c; IR = immediate release; XR = extended release; ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker. FORXIGA ® and XIGDUO ® XR are registered trademarks and INSPIREdiabetes is a trademark of the AstraZeneca group of companies. Registered user AstraZeneca Pty. Ltd. ABN 54 009 682 311. 66 Talavera Road, Macquarie Park, NSW 2113. AstraZeneca Medical Information or to report an adverse event: 1800 805 342. August 2017. AU-3236. 14423.